ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2530

Patient´s Motivations for Non-Persistence with Medication Impact How They Score Compliance

Irazú Contreras-Yáñez1, Diana Isabel Pérez-Román2 and Virginia Pascual-Ramos3, 1Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Department of Immunology and Rheumatology., Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán., Mexico City, Mexico, 3Mexican Accreditation Council of Rheumatology, A.C., Mexico City, Mexico

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Compliance and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: In 2004 we initiated a cohort of rheumatoid arthritis (RA) patients with recent-onset disease. From 2008 onwards, both construct of compliance, persistence on therapy (P) and adherence with therapy (A) were prospectively assessed through a questionnaire (the CQ) that additionally investigated motivations for non-P, and a visual analogue scale for C (C-VAS). We hypothesized that how a patient subjectively attributed a motivation (patient-dependent vs. patient independent) impacted his/her evaluation of C. Objectives were to examine the correlation between compliance assessed as per the CQ and per the VAS, and to investigate if the selection of patient-independent motivation for non-P predicted better score of C.

Methods: Up to January 2016, the cohort comprised 180 patients with variable follow-up. Since 2008, CQ and C-VAS were concomitantly applied at regular six-months apart-intervals. The CQ is a 22-items questionnaire, where item 11 investigates 15 predefined patient´s motivations for non-P and one open answer; a patient is considered CQ-compliant if A and P. The C-VAS is a 100 mm VAS, where 0 indicates “very good compliance”. Each motivation for non-P was classified as patient-dependent or patient-independent by 50 patients randomly selected and directly interviewed to such purpose (≥70% agreement among the patients interviewed). Multiple regression analysis was used to evaluate patient-independent motivation as a predictor of better compliance. The study was approved by the institution’s internal review board. Written informed consent was obtained.

Results: The final number of patients for which data were analyzed was 160. At inclusion in the cohort, patients were primarily middle-age female (90%), with 5.4±2.6 months of disease duration and high disease activity. The majority had RF (85.6%) and antibodies to cyclic citrullinated peptides (88.1%). To January 2016, the (mean±SD) length of follow-up was 6.7±3.4 years, during which patients completed 1516 pairs of CQ and C-VAS. The C-VAS significantly correlated with the CQ, r=0.468, p=0.001. Cut-off value of C-VAS to predict CQ-compliance was 7.5 mm. During follow-up, there 670 CQs scored as with non-P among whom, 654 had at least one motivation for non-P selected; of them, 549 CQs (70.2%) corresponded to non-P patients who selected only patient-independent motivations and 31 (4.7%) to those who selected only patient-dependent motivations. Patients from the former group had better C-VAS scores than their counterparts. The selection of exclusively independent motivations for non-P predicted C-VAS score and CQ score, ß: -0.15, 95%CI: -19.2 to -6.8, p≤0.001 and ß: 0.79, 95%CI: 0.01-0.819, p=0.045, respectively. Also, the selection of exclusively independent motivations for non-P predicted VAS-compliance (OR: 15.6, 95%CI: 5.4-45.3, p≤0.001) and CQ-compliance (OR: 2.25, 95%CI: 1.062-4.664, p=0.034).

Conclusion: Patient´s motivations for non-P impact how they perceived and scored their compliance; a potential consequence of such behavior is that non-compliant patients may be misidentified.


Disclosure: I. Contreras-Yáñez, None; D. I. Pérez-Román, None; V. Pascual-Ramos, None.

To cite this abstract in AMA style:

Contreras-Yáñez I, Pérez-Román DI, Pascual-Ramos V. Patient´s Motivations for Non-Persistence with Medication Impact How They Score Compliance [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/patients-motivations-for-non-persistence-with-medication-impact-how-they-score-compliance/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patients-motivations-for-non-persistence-with-medication-impact-how-they-score-compliance/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology